Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ERAS
Erasca, Inc. Common Stock
stock NASDAQ

At Close
Aug 7, 2026 3:59:59 PM EDT
18.40USD+0.712%(+0.13)2,096,111
0.00Bid   0.00Ask   0.00Spread
Pre-market
Aug 6, 2026 9:17:30 AM EDT
18.56USD+1.584%(+0.29)0
After-hours
Aug 7, 2026 4:16:30 PM EDT
18.84USD+2.391%(+0.44)503,518
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 18, 2022
08:00AM EST  Erasca Strengthens Leadership Team with Two Key Executive Appointments   GlobeNewswire Inc
Jan 11, 2022
10:38AM EST  52 Weeks High And Low Article   Benzinga
Jan 4, 2022
08:00AM EST  Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference   GlobeNewswire Inc
Dec 17, 2021
08:08AM EST  Erasca Reports FDA Clearance For Its Investigational New Drug Application For ERAS-801 In Glioblastoma Multiforme; Collab With GCAR For Potential Inclusion Of AGILE Trial   Benzinga
08:00AM EST  IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial inrecurrent GBM anticipated in Q1 2022   GlobeNewswire Inc
Dec 14, 2021
08:18AM EST  Erasca Added To The Nasdaq Biotechnology Index   Benzinga
08:00AM EST  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.   GlobeNewswire Inc
Nov 16, 2021
08:00AM EST  Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference   GlobeNewswire Inc
Nov 10, 2021
05:26PM EST  Erasca Q3 EPS $(0.46) Up From $(0.50) YoY   Benzinga
Oct 25, 2021
04:01PM EDT  Erasca Announces Presentation Of Preclinical Data On ERAS-801 At AACR Conference On Brain Cancer   Benzinga
04:01PM EDT  ERAS-801's CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII and wildtype alterationsImproved outcomes in over 90% of EGFR-driven patient-derived glioblastoma modelsIND submission in refractory glioblastoma planned for Q1 2022   GlobeNewswire Inc
Sep 27, 2021
08:01AM EDT  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Fierce Biotech has named it as one of 2021s Fierce 15 biotechnology companies, identifying Erasca as one of the industrys most promising biotechnology companies.   GlobeNewswire Inc
Sep 22, 2021
08:01AM EDT  Erasca Reports First Patient Was Dosed In HERKULES-3 Phase 1b/2 Gastrointestinal CAncer Master Protocol Evaluating ERAS-007 In Multiple Combos   Benzinga
08:00AM EDT  Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2   GlobeNewswire Inc
Sep 9, 2021
08:03AM EDT  Erasca Announces First Patient Dosed In HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 In Multiple Combinations   Benzinga
08:00AM EDT  Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung   GlobeNewswire Inc
Sep 8, 2021
08:26AM EDT  Erasca Announces Clinical Trial Collaboration And Supply Agreement With Pfizer To Evaluate ERAS-007 And Encorafenib Combination   Benzinga
08:00AM EDT  ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC)   GlobeNewswire Inc
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
08:00AM EDT  Erasca to Participate in the Morgan Stanley 19th Annual Global   GlobeNewswire Inc
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
04:03PM EDT  Erasca Q2 EPS $(1.20) Down From $(0.26) YoY   Benzinga
04:01PM EDT  Erasca Reports Second Quarter 2021 Financial Results and Business   GlobeNewswire Inc
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
10:32AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021   Benzinga
10:15AM EDT  Evercore ISI Group Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $45   Benzinga
07:41AM EDT  Morgan Stanley Initiates Coverage On Erasca with Equal-Weight Rating, Announces Price Target of $25   Benzinga
07:40AM EDT  B of A Securities Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $28   Benzinga
07:36AM EDT  Guggenheim Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $25   Benzinga
05:36AM EDT  JP Morgan Initiates Coverage On Erasca with Overweight Rating, Announces Price Target of $28   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 21, 2021
07:52AM EDT  The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay   Benzinga
Jul 20, 2021
04:01PM EDT  Erasca Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
Jul 16, 2021
12:57PM EDT  Erasca Shares Open For Trade At $15.90; IPO Priced At $16/Share   Benzinga
09:58AM EDT  Erasca Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $16/Share   Benzinga
Jul 15, 2021
09:59PM EDT  Erasca Announces Pricing of Upsized Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC